New Mexico State Society of AMT
|
|
|
|
Our first speaker was Laurel Christensen, CLC. She spoke
about the final Clinical Laboratory Improvement Amendments (CLIA) rules and
There are other changes, such as, how often quality control specimens
Our second speaker was Gerald Davis, MT who presented a review of the
production and maturation of red blood cells. He showed slides
demonstrating the various stages of development as well as normal and abnormal
red blood
cells. Gerald discussed some medical conditions which cause various
changes in
After lunch, Gerald continued his presentation with a review of the production and maturation of white blood cells. He showed slides demonstrating the morphology of developing stages including normal and abnormal white blood cells. Gerald discussed various forms of leukemia and other conditions that produce
blasts and early cells in the blood stream. He also covered platelet
formation and a variety of diseases that can cause a shortage of peripheral
platelets which can lead to abnormal bleeding. Gerald provided those who perform hematology procedures with a good review and others with a good introduction of Red and White blood cells. Business and Board meetings were held following a brief break. Our next meeting will be held at Pima Medical Institute on Saturday September 23.
|
Send mail to
rpolasky@familyplace.com with questions or comments about this web site.
|
The
Spring 2006 meeting for NMSSAMT was held on Saturday September 24th at the Pima
Medical Institute in Albuquerque.
Equivalent
Quality Control (EQC). The intent of the final rules is to promote
development, implementation, delivery, monitoring, and improvement of laboratory
services. There are three areas of concern which are: pre-analytic,
what happens to the test before its tested, proper paperwork, specimen handling,
and how testing materials are treated; analytic, what happens to the specimen
during the test, testing environment, testing materials, and how the test is
done; and post-analytic, what happens to the test results after the test on the
specimen is completed.
Some of the changes are in nomenclature. Such as, "non-waived" replaces
high and moderate complexity testing. There are a large number of waived
tests and the remaining tests tend to be of high complexity. Waived tests
require no special personnel training.
However,
the requirements for personnel performing complex testing did not change.
should be run and how reference ranges should be determined. All
laboratory directors and supervisors must be familiar with any and all changes
in the CLIA Rules.
the red cells.
